The obsessive-compulsive disorder (OCD) market is projected to grow significantly, reaching approximately $1.0 billion by 2034, driven by advancements in treatment and increased awareness, according to a new report from DelveInsight. The report highlights a growing demand for innovative therapies and the potential for new medical devices to transform the treatment landscape for OCD patients globally.

Market Growth and Key Players

The OCD market size was valued at around USD 1,000 million in 2023 and is expected to grow at a significant compound annual growth rate (CAGR) from 2020 to 2034. The United States accounted for approximately USD 600 million of that market, while the EU4 countries and the UK contributed around USD 380 million.

Leading pharmaceutical companies such as Biohaven Pharmaceuticals, AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, and others are actively developing and commercializing new treatments for OCD. In 2023, selective serotonin reuptake inhibitors (SSRIs) generated roughly USD 290 million in revenue across seven major markets, while antipsychotics earned around USD 160 million.

Breakthrough Treatments and Market Innovations

In August 2025, neurocare group AG received FDA clearance for its Apollo TMS Therapy device for the treatment of OCD, expanding the range of non-invasive mental health treatment options available. This approval highlights the growing interest in alternative and minimally invasive treatments for OCD.

In December 2024, researchers conducted the first-ever clinical trial using magnetic resonance-guided focused ultrasound (MRgFUS) capsulotomy for individuals with treatment-resistant OCD. A decade-long follow-up study found that patients experienced lasting symptom relief, improved daily functioning, and strong patient satisfaction. These findings highlight MRgFUS capsulotomy as a promising, safe, and effective treatment option for OCD patients globally.

Epidemiology and Patient Demographics

In 2023, the United States had approximately 2.1 million diagnosed prevalent cases of OCD, with the seven major markets (7MM) having around 320,000 mild cases, 760,000 moderate cases, and 1,100,000 severe cases. The report also noted that approximately 22% of OCD cases in the EU4 and the UK were male, while about 78% were female.

The epidemiology section of the report provides insights into historical, current, and forecasted trends in OCD prevalence across the 7MM from 2020 to 2034. It includes detailed analysis of diagnosed patient pools, severity-based prevalence, and gender-specific trends. The report emphasizes that OCD occurs more frequently in females than in males.

The market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. The launch of various multi-stage pipeline products is anticipated to significantly revolutionize the OCD market dynamics.

Therapeutic Landscape and Key Companies

The report identifies several key therapies for OCD, including Troriluzole, Fluvoxamine maleate, BHV-4157, Quetiapine, Reclaim®, Bitopertin, topiramate, Escitalopram, Duloxetine, Paliperidone, and pregabalin. Each of these therapies is being developed by major pharmaceutical companies such as Biohaven Pharmaceuticals, AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, and others.

For example, Troriluzole is being developed by Biohaven Pharmaceuticals, while Fluvoxamine maleate is being marketed by AbbVie. The report also highlights the importance of therapies with novel mechanisms of action (MoA) to improve efficacy and reduce side effects, as current treatments such as SSRIs, antipsychotics, and cognitive behavioral therapy (CBT) have limitations.

According to the report, the expected approval of troriluzole, a late-stage drug candidate with a novel mechanism of action, is likely to drive the OCD market forward. However, the market faces challenges, including the need for more personalized treatment approaches based on clinical, environmental, and biological predictors of response.

The report also covers pipeline development activities, including collaborations, acquisitions, mergers, and licensing agreements among key players in the OCD market. These developments are expected to shape the future of OCD treatment and market dynamics.

As the demand for effective OCD treatments continues to grow, the report suggests that investors and pharmaceutical companies should pay close attention to the evolving therapeutic landscape and the potential for new medical technologies to address unmet patient needs.